Strong Physical

Creatine: Which Form, How Much, and the Myths

Name: Creatine: Which Form, How Much, and the Myths
Creator: Realised
Published: 2026-06-01

Summary

Creatine is the most-studied, most-effective legal performance supplement there is — and the form question has a boring, settled answer: plain monohydrate, 3–5 g a day, is the gold standard; every "advanced" form charging a premium (HCl, buffered, ethyl ester, liposomal) has either failed to beat it head-to-head or performed worse, and the kidney/bloat fears that scare people off are unfounded in healthy users.

Why Strong

Tier 1 because: the efficacy of monohydrate and the form comparisons rest on a large RCT literature and an ISSN position stand; the buffered-parity (biopsy RCT) and ethyl-ester-inferiority findings are direct head-to-head trials; and the safety/creatinine-artifact points are well-established physiology.

NOT Tier 0.5 because it involves practical judgement (tolerability fallbacks, loading-or-not) and a genuine two-sided commercial controversy, not a single undisputed axiom.
NOT Tier 2 because the core claims are not "a few suggestive studies" — they are replicated RCTs plus consensus; only the form-specific comfort edge and the hair-loss question sit lower, and the entry treats them as such.

Practical takeaway

The one rule: buy plain creatine monohydrate (ideally a quality-tested brand such as Creapure / third-party certified), take 3–5 g every single day, and ignore the premium shelf. That is the whole protocol.
• Loading: optional. In a hurry (e.g., pre-season)? ~20 g/day split for 5–7 days, then 3–5 g/day. Otherwise just take 3–5 g/day and you reach the same place in ~3–4 weeks.
• Timing: doesn't meaningfully matter — take it whenever you'll remember it daily. Taking it with a meal/carbs is a marginal, optional optimisation.
• Who benefits most: anyone doing resistance or repeated high-intensity training. Vegetarians/vegans start with lower muscle creatine (dietary creatine comes from meat/fish) and tend to see the largest response.
• Form exceptions: if monohydrate genuinely upsets your gut, micronised monohydrate or splitting the dose usually fixes it before you need to pay up for HCl. The premium forms are a tolerability fallback at best, never an efficacy upgrade.
• Don't cycle it. There is no need to cycle on/off; steady daily intake keeps stores topped up.
• The water gain is the point, not a side effect. Expect a small (~0.5–1.5 kg) early scale bump — that is intracellular water in muscle, not fat and not subcutaneous "bloat."

For the cognitive/sleep-deprivation angle (creatine partially buffering the cognitive cost of poor sleep), defer to sleep_creatine_deprivation; for where creatine sits among the genuinely worth-it supplements, see universal_nearuniversal_supplementation.

Evidence detail

Why This Entry Exists

Walk into any supplement shop and the creatine shelf has a cheap tub of monohydrate at the bottom and a row of "Kre-Alkalyn," "creatine HCl," "creatine ethyl ester," "liposomal," "creatine magnesium chelate" at 3–15× the price, each promising better absorption, no loading, no bloat. The marketing has done its job: a huge share of buyers believe monohydrate is the old, crude form they've upgraded away from. They are paying more for less evidence.

This entry is the home of record for the two questions a user actually has — which form, and is it safe — and it answers both against independent data, not the label. The short version: the premium-form market is built on a real chemistry fact (some forms dissolve better) that does not translate into a single measurable advantage in muscle creatine, strength, power, or body composition. Meanwhile the two fears that make people quit — "it wrecks your kidneys" and "it makes you bloated" — are a lab-marker artifact and a benign, mostly-intracellular water gain respectively.

What bad advice this protects against, in both directions:
• Buying the premium form → you pay 3–15× for solubility you don't need (monohydrate is already ~99% bioavailable) and, in the case of ethyl ester, you actually get less creatine into the muscle.
• Avoiding creatine over kidney/bloat fear → you skip one of the few supplements with Tier-1 evidence because of a misread blood test and a misunderstanding of where the water goes.
• Over-complicating it → loading phases, special timing, cycling on/off — none of it is required; the protocol is "take 3–5 g every day."

It does not re-argue whether creatine works for strength/muscle (that is the assumed background, see resistance_training_and_body_composition) or its cognitive/sleep-deprivation role (owned by sleep_creatine_deprivation). It owns form selection, dosing, and myth-correction.

Evidence

1. Monohydrate is the benchmark no other form has beaten (Tier 1). The International Society of Sports Nutrition position stand (Kreider et al., 2017) names creatine monohydrate the most effective and by far the most-studied ergogenic supplement for increasing muscle creatine, high-intensity performance, and lean mass — and states no other form has been shown superior. Every premium form is measured against monohydrate, and the burden of proof it has to clear is "beat the most-researched supplement in sports nutrition." None has.

2. Buffered creatine (Kre-Alkalyn) = parity, not superiority (Tier 1). Jagim et al. (2012), a double-blind RCT (n=36, 28 days, with muscle biopsies), compared buffered creatine against monohydrate at both the manufacturer's lower "no-loading" dose and an equal-loading dose. Result: the same increase in muscle total creatine, the same strength and body-composition changes — no advantage at either dose. (Notably the trial was funded by a monohydrate manufacturer, AlzChem — but the finding is parity, not "monohydrate wins," so funding bias is an unlikely explanation for a null.)

3. Ethyl ester is actively worse (Tier 1). Spillane et al. (2009), double-blind RCT (n=30, 7 weeks), found creatine ethyl ester (CEE) raised serum and muscle creatine less than monohydrate, and raised serum creatinine more — consistent with CEE rapidly degrading to creatinine before it can be taken up. So this is not "no better": it is inferior, and it inflates the very blood marker people misread as kidney damage.

4. The HCl pitch is a solubility fact that doesn't cash out (Tier 1–2). Creatine HCl's headline is ~38× higher water solubility than monohydrate. That is true chemistry — and performance-irrelevant: monohydrate is already absorbed at ~99%, so there is no absorption problem for greater solubility to fix, and no trial shows HCl producing greater muscle creatine or performance at effective doses. Its only plausible real-world edge is a smaller pill/scoop volume and possibly less GI discomfort for the minority who get it on monohydrate — a comfort argument, weakly evidenced, not an efficacy one.

5. Dose and loading (Tier 1). Maintenance is 3–5 g/day. A loading phase (~20 g/day split into 4 doses for 5–7 days) saturates muscle stores faster but is optional — 3–5 g/day reaches the same plateau in ~3–4 weeks. Loading buys speed, not a bigger end-state. Daily consistency matters far more than timing; "with carbs/post-workout" tweaks are marginal.

6. The kidney fear is unfounded in healthy people (Tier 1). The ISSN position stand concludes there is no evidence of renal harm in healthy individuals, including long-term and high-dose use (up to 30 g/day, and multi-year use in patient populations). The fear largely traces to creatine raising serum creatinine — but creatinine is a downstream breakdown product of creatine, so a higher reading after supplementation is a measurement artifact, not evidence of reduced kidney function. (Caveat retained below for pre-existing renal disease and pregnancy, where data are lacking rather than reassuring.)

Mechanism

What creatine does. Creatine is stored in muscle as phosphocreatine (PCr), the rapid-recharge reservoir for regenerating ATP during short, intense efforts. More PCr → a few more high-quality reps / more total training volume → more accumulated stimulus over weeks. It also draws water into the muscle cell (cell volumisation), which is part of both the small scale-weight bump and, plausibly, the anabolic signal.

Why monohydrate already wins on absorption. Monohydrate dissolves adequately in the gut and is absorbed at ~99% — it does not survive as creatine in blood because it is taken up, not because it is degraded. There is simply no bioavailability gap for an "advanced" form to close.

Why solubility ≠ efficacy. Solubility in the glass (HCl's selling point) predicts neither gut absorption nor muscle uptake when absorption is already near-complete. Muscle creatine transport is the rate-limiting step, and it is saturable — once stores are full, extra delivery does nothing. This is why every form converges on the same muscle saturation at adequate doses.

Why ethyl ester underperforms. Esterification was meant to improve cell-membrane permeability, but CEE is unstable at stomach pH and degrades to creatinine before uptake — delivering less usable creatine and more of the inert breakdown product (hence the larger creatinine rise).

Why the creatinine reading is benign. Serum creatinine is the standard kidney-function proxy precisely because it is creatine's metabolite. Supplementing creatine raises the substrate pool, nudging creatinine up without any change in glomerular filtration. A clinician who knows you supplement reads it correctly; cystatin C is the cleaner kidney marker if there is genuine concern.

Risks And Contraindications

• Healthy kidneys: no evidence of harm, including long-term/high-dose use. The creatinine rise is an artifact — tell any clinician interpreting your bloods that you supplement creatine (or ask for cystatin C).
• Keep the caveat honest, not absolutist: evidence of safety is robust for healthy people. Those with pre-existing renal disease should use only with medical oversight, and creatine is not well-studied in pregnancy — "no evidence of harm in healthy adults" is not "proven safe for everyone."
• GI discomfort can occur, usually at high single doses or during loading — split the dose or drop the load.
• The "water weight / bloat" worry is largely a misunderstanding: the gain is intracellular muscle water, benign, and does not cause subcutaneous puffiness or dehydration (creatine does not dehydrate you; older "cramping/dehydration" claims are not supported).
• Hair loss / DHT: rests almost entirely on a single 2009 college-rugby study (van der Merwe et al.) showing a rise in DHT — never replicated, and no study has shown creatine causes hair loss. Honest read: not a demonstrated risk, but not something to flatly dismiss for someone with strong androgenetic-alopecia predisposition who wants to be cautious. Watch-and-see, don't fearmonger.
• Quality: creatine is cheap, so adulteration incentive is low, but buy third-party-tested (Creapure / NSF / Informed-Sport) to avoid contamination — see supplement_form_elemental_dose_and_bioavailability for the label-literacy principle.

Controversy

Nature: commercial / form-marketing, with overstatement at both poles.

Position A — "All forms are basically the same, just buy the cheapest." The casual take.
• Best evidence: largely correct — monohydrate matches or beats every alternative, so cheapest-quality-monohydrate is the rational buy.
• Where it's incomplete: ethyl ester is genuinely worse (not merely equal), and for a minority, GI tolerance is a real reason to choose micronised or split dosing — so "all the same" isn't perfectly true, just close.

Position B — "Advanced forms (HCl, Kre-Alkalyn, liposomal) are superior; monohydrate is outdated." The supplement-marketing take.
• Best evidence: HCl really is more soluble; some users report less bloating on certain forms.
• Where it's wrong: solubility and self-reported comfort are not efficacy; head-to-head RCTs show parity (Kre-Alkalyn) or inferiority (ethyl ester), and no form beats monohydrate on muscle creatine, strength, power, or lean mass. The premium price buys no demonstrated benefit.

The funding/bias dimension: the industry profits at both ends — selling "next-generation" forms at a markup on absorption stories, while the strongest monohydrate evidence comes from a deep, decades-long, partly independent literature (and even an industry-funded buffered-creatine trial returned parity, which cuts against its sponsor's interest). The clean signal — ISSN consensus + the biopsy and serum RCTs — lands on monohydrate.

Realised Position: Buy plain, quality-tested monohydrate; take 3–5 g/day; loading optional; don't cycle. The kidney and bloat fears are unfounded in healthy people (creatinine rise is an artifact; the water is intracellular and benign). Premium forms are a tolerability fallback, not an upgrade — the only honest reason to switch is GI comfort, never performance. Keep the pregnancy/renal-disease caveat visible rather than declaring it universally safe.

Cross-Pillar Connections

• Physical (resistance_training_and_body_composition): that entry owns whether/how creatine helps training adaptation; this entry owns which form and how to dose it.
• Diet (universal_nearuniversal_supplementation, diet_protein_intake): creatine sits among the short list of genuinely worth-it supplements; vegetarians (low dietary creatine) respond most.
• Sleep / Cognition (sleep_creatine_deprivation): the emerging cognitive/sleep-deprivation-buffering role lives there — this entry defers to it rather than duplicating.
• Label literacy (supplement_form_elemental_dose_and_bioavailability): same parent principle — the label/marketing is not where the answer is; the independent data are.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd upgrade a specific premium form if independent, adequately-powered RCTs showed it producing greater muscle creatine or superior strength/lean-mass outcomes than monohydrate at matched effective doses — solubility or single-blind comfort surveys would not suffice.
• We'd revise the safety stance if well-controlled long-term studies showed renal harm in healthy users (current high-dose, multi-year data show none), or if creatine were shown to cause hair loss beyond the single unreplicated DHT signal.
• What would NOT move us: the ~99% bioavailability of monohydrate (no absorption gap to fix), the serum-creatinine artifact, or the benign intracellular nature of the water gain — these are settled.

Industry bias note

Structural incentives the evidence base may reflect

This is a topic where the supplement industry profits chiefly at the premium end, which is exactly why the independent/consensus data are the anchor.
• The premium end: "advanced" forms (HCl, Kre-Alkalyn, ethyl ester, liposomal, magnesium chelate) command 3–15× the price of monohydrate on absorption/no-bloat/no-loading narratives that head-to-head trials do not support.
• The fear-driven end: the "creatine wrecks your kidneys / makes you bloated" memes suppress use of a cheap, effective supplement — a contrarian overcorrection not supported by the renal data.
• The clean signal: the ISSN 2017 position stand, the Jagim 2012 biopsy RCT (parity despite pro-monohydrate funding), and the Spillane 2009 ethyl-ester RCT converge on the boring truth — monohydrate, 3–5 g/day, is the answer. Realised weights those over both the premium-form marketing and the kidney-scare counter-narrative.

Sources (6)

Open in the Library: search, filter, every entry →